Clinical trial
A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy and Pharmacodynamics of IMG-7289 in Patients With Essential Thrombocythemia
NCT04254978 is registered in ClinicalTrials.gov with Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy and Pharmacodynamics of IMG-7289 in Patients With Essential Thrombocythemia
- Lead sponsor
- Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 8, 2020
- Completion date
- March 23, 2023
- Enrollment
- 73 (actual)
- Sites
- 26
Conditions
As the registry lists them; a condition with its own page is linked.
essential thrombocythemia